Epidemiology and treatment status of hepatitis C virus infection among people who have ever injected drugs in South Korea: a prospective multicenter cohort study from 2007 to 2019 in comparison with non-PWID
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
OBJECTIVES: Injection drug use is a major risk factor for hepatitis C virus (HCV) infection; however, limited data on this topic are available in Korea. Thus, this study aimed to investigate the epidemiological and clinical characteristics, treatment uptake, and outcomes of HCV infection among people who inject drugs (PWID). METHODS: We used the data from the Korea HCV cohort, which prospectively enrolled patients with HCV infection between 2007 and 2019. Clinical data and results of a questionnaire survey on lifetime risk factors for HCV infection were analyzed according to a self-reported history of injection drug use (PWID vs. non-PWID group). RESULTS: Among the 2,468 patients, 166 (6.7%) were in the PWID group, which contained younger patients (50.6± 8.2 vs. 58.2± 13.1 years) and a higher proportion of male (81.9 vs. 48.8%) than the non-PWID group. The distribution of PWID showed significant regional variations. Exposure to other risk factors for HCV infection was different between the groups. The proportion of patients with genotype non-2 infection was higher in the PWID group. Treatment uptake was higher in the PWID group in the interferon era; however, it was comparable between the groups in the direct-acting antiviral era. The rate of sustained virological response did not significantly differ between the groups. CONCLUSIONS: As of 2019, PWID constituted a minority of HCV-infected people in Korea. The epidemiological characteristics, but not treatment uptake and outcomes, were different between the PWID and non-PWID groups. Therefore, active HCV screening and treatment should be offered to PWID in Korea.
Abstract
OBJECTIVES: Injection drug use is a major risk factor for hepatitis C virus (HCV) infection; however, limited data on this topic are available in Korea. Thus, this study aimed to investigate the epidemiological and clinical characteristics, treatment uptake, and outcomes of HCV infection among people who inject drugs (PWID). METHODS: We used the data from the Korea HCV cohort, which prospectively enrolled patients with HCV infection between 2007 and 2019. Clinical data and results of a questionnaire survey on lifetime risk factors for HCV infection were analyzed according to a self-reported history of injection drug use (PWID vs. non-PWID group). RESULTS: Among the 2,468 patients, 166 (6.7%) were in the PWID group, which contained younger patients (50.6± 8.2 vs. 58.2± 13.1 years) and a higher proportion of male (81.9 vs. 48.8%) than the non-PWID group. The distribution of PWID showed significant regional variations. Exposure to other risk factors for HCV infection was different between the groups. The proportion of patients with genotype non-2 infection was higher in the PWID group. Treatment uptake was higher in the PWID group in the interferon era; however, it was comparable between the groups in the direct-acting antiviral era. The rate of sustained virological response did not significantly differ between the groups. CONCLUSIONS: As of 2019, PWID constituted a minority of HCV-infected people in Korea. The epidemiological characteristics, but not treatment uptake and outcomes, were different between the PWID and non-PWID groups. Therefore, active HCV screening and treatment should be offered to PWID in Korea.
참고문헌 (25)
- "Global hepatitis report" (2017)[URL]
- European Association for the Study of the Liver, "EASL recommendations on treatment of hepatitis C : final update of the series", J Hepatol, 73, pp.1170~1218 (2020)
- "Combating hepatitis B and C to reach elimination by 2030" (2016)[URL]
- Jafri SM, "Epidemiology of hepatitis C", Clin Liver Dis(Hoboken), 12, pp.140~142 (2018)
- Stasi C, "Update on hepatitis c epidemiology:unaware and untreated infected population could be the key to elimination", SN Compr Clin Med, pp.1~8 (2020)
- Shiffman ML, "The next wave of hepatitis C virus : the epidemic of intravenous drug use", Liver Int, 38(Suppl 1), pp.34~39 (2018)
- Grebely J, "Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs", Addiction, 114, pp.150~166 (2019)
- Jang ES, "The change in the nationwide seroprevalence of hepatitis C virus and the status of linkage to care in South Korea from 2009 to 2015", Hepatol Int, 13, pp.599~608 (2019)
- Kyung-Ah Kim, "Prevalence, Awareness, and Treatment of Hepatitis C Virus Infection in South Korea: Evidence from the Korea National Health and Nutrition Examination Survey", Gut and Liver, 14(5), pp.644~651 (2020), 거트앤리버 소화기연관학회협의회[DOI]
- Min JA, "Prevalence and associated clinical characteristics of hepatitis B, C, and HIV infections among injecting drug users in Korea", J Med Virol, 85, pp.575~582 (2013)
- Yun H, "High prevalence of HBV and HCV infection among intravenous drug users in Korea", J Med Virol, 80, pp.1570~1575 (2008)
- Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC, "2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma", Gut and Liver, 13(3), pp.227~299 (2019), 거트앤리버 소화기연관학회협의회[DOI]
- Joon Yeul Nam, "Epidemiological and Clinical Characteristics of Hepatitis C Virus Infection in South Korea from 2007 to 2017: A Prospective Multicenter Cohort Study", Gut and Liver, 14(2), pp.207~217 (2020), 거트앤리버 소화기연관학회협의회
- 김경아, "Geographic difference of epidemiological features of HCV infection in Korea", Clinical and Molecular Hepatology, 20(4), pp.361~367 (2014), 대한간학회
- Grebely J, "Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs", Addiction, 114, pp.150~166 (2019)
- Degenhardt L, "Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs : a multistage systematic review", Lancet Glob Health, 5, pp.e1192~e1207 (2017)
- "Statistics on the illegal drug use in Republic of Korea"[URL]
- Seong MH, "Clinical and epidemiological features of hepatitis C virus infection in South Korea : a prospective, multicenter cohort study", J Med Virol, 85, pp.1724~1733 (2013)
- Trickey A, "The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level : a modelling study", Lancet Gastroenterol Hepatol, 4, pp.435~444 (2019)
- Erman A, "Estimation of fibrosis progression rates for chronic hepatitis C : a systematic review and meta-analysis update", BMJ Open, 9, pp.e027491~ (2019)
- Smith DJ, "Hepatitis C virus(HCV)disease progression in people who inject drugs(PWID) : a systematic review and meta-analysis", Int J Drug Policy, 26, pp.911~921 (2015)
- Mehta SH, "Limited uptake of hepatitis C treatment among injection drug users", J Community Health, 33, pp.126~133 (2008)
- Grebely J, "Barriers associated with the treatment of hepatitis C virus infection among illicit drug users", Drug Alcohol Depend, 93, pp.141~147 (2008)
- Falade-Nwulia O, "Hepatitis C treatment uptake among people who inject drugs in the oral direct-acting antiviral era", Liver Int, 40, pp.2407~2416 (2020)
- Graf C, "Efficacy of direct-acting antivirals for chronic hepatitis C virus infection in people who inject drugs or receive opioid substitution therapy : a systematic review and meta-analysis", Clin Infect Dis, 70, pp.2355~2365 (2020)